Introduction
============

It is widely believed that platelet responsiveness can be used as a marker for assessing thrombotic risk in patients. Therefore, there have been many attempts to develop suitable assays for quantifying platelet responses in clinical samples [@B1]. Platelet aggregometry is widely used, but is limited in its ability to assess platelet hyper-responsiveness. In order to develop a better assay of thrombotic risk, we use a novel assay to evaluate platelet secretion of adenosine triphosphate & diphosphate (ATP/ADP) in response to various agonists. This assay measures both the maximal amount of adenine nucleotides released by a range of platelet activators and the potency of each activator.

Methods
=======

To determine the reproducibility of this assay, we assessed 4 healthy female subjects on 3 separate occasions. 10mls of blood was drawn from subjects who had abstained from medication for the previous 12 days. Platelet ATP/ADP secretion was assessed in a 96 well assays as previously described [@B2]. Briefly, platelet secretion is assessed in response to increasing doses of platelet agonists (Thrombin receptor activating peptide: TRAP 0.1-32µM; Collagen related peptide: CRP 0.05-100µg/ml). Released ATP/ADP is measured using firefly luciferase (Chronolume Corp). Data are expressed as nmoles ATP/ADP secreted per 10^6^ platelets. Dose-response curves are constructed and analysed using GraphPad Prism 5.0.

Results
=======

The maximal amount of ATP/ADP released is similar for both agonists tested (1.94±0.25 and 2.12±0.28 nmoles per 10^6^ platelets in response to TRAP and CRP, respectively). However, the potency of responses, measured as EC~50~ values, differed for the two agonists. For TRAP, the EC~50~ values were equivalent in all 4 donors (mean EC~50~ value is 4.84 ±0.30µM; range 4.38-5.57µM). in response to CRP, the potency of the responses were nearly similar for all the donors (EC~50~ range from 0.37µg/ml to 1.08µg/ml). Nonetheless, there is a high degree of concordance within all samples from any one donor.

Conclusion
==========

Our data demonstrate that individual donors display unique response-parameters which may be used to assess thrombotic risk. In addition, we can conclude that the dose of agonist that causes a half-maximal response is a reliable index of platelet responsiveness.
